印度藥品市場分析及預測：2008年至2023年

印度藥品市場分析及預測：2008年至2023年 是由出版商Visiongain在2008年05月所出版的。 這份英文市場調查報告書包含175 pages 價格從美金2331起跳。

簡介

封面圖片：

目錄

Abstract

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry' s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world' s most important healthcare markets from the present onwards.

This new visiongain report describes India' s domestic as well as export market for pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly expanding market with a population of over a billion and a rapidly expanding economy. Prevalence values of many diseases are likely to increase with expansion of population, urbanisation and with higher identification rates in the coming decade. India' s pharmaceutical market is increasingly important in global pharma, with both domestic and foreign companies benefiting. Healthcare provision - both public and private - is improving, leading to fast-expanding markets for healthcare products, especially modern pharmaceuticals, visiongain concludes.

Outsourcing for Contract Research and Manufacturing Services from India

The report also analyses India' s role in pharma outsourcing services. India is emerging as a competitive outsourcing hub and is playing a major role in the global pharmaceutical industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical companies are establishing long-term relationships with Indian manufacturing companies and contract research providers in India.

Generic drugs produced in India are increasingly being accepted worldwide, with leading companies such as Ranbaxy, Cipla and Dr. Reddy' s paving the way for others. Indian companies have increasingly taken on outsourced manufacturing for foreign clients, in addition to marketing pharmaceuticals themselves. There are also new drug development programmes by Indian companies, with eventual international market launches. Outsourcing to India has proven to be effective in saving costs and valuable developmental time. The Indian pharmaceutical industry has taken an important role in global pharma, not only as a manufacturer of generic drugs and APIs but also of new formulations.

Increasing costs for research and development and low productivity have compelled major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to lower-cost, developing nations such as India and China. India' s emphasis on research and development and new drug discovery is growing. Furthermore, India is emerging as the preferred destination for outsourcing clinical trials, with both high quality and lower costs achieved there.

• With the introduction of ' product patent regime' in 2005, India is expected to receive further investment from international pharmaceutical companies in the years ahead
• Global pharmaceutical companies are establishing long-term relationships with Indian pharmaceutical companies and the contract manufacturing affiliates in India, in addition to establishing manufacturing, R&D and marketing bases there

Why You Should Buy This Report

In this report you will receive the following essential information for understanding the Indian pharma market and industry:

• The value of the Indian pharmaceutical market and its principal market segments from 2008 to 2023
• Exports values of the Indian pharmaceutical sector present and future
• Which current or future therapies that will drive the market for India' s pharmaceutical industry from 2008 to 2023
• Market drivers and restraints, including a comprehensive SWOT analysis
• Comprehensive views of key opinion leaders on Indian pharma
• The companies involved in the market and their business strategy
• What are the forecasts for sales for each of the therapeutic areas
• What is the present state of disease prevalence and future trends there
• What contract research and manufacturing opportunities exist for ' new comers'

This Report is essential reading for the Following Professionals, Amongst Others:

• Investors in the India' s pharmaceutical industry
• Business managers of multinational companies
• Business managers of India' s domestic companies
• Business managers of pharmaceutical industry related to outsourcing
• Researchers, analysts and academics interested in India' s pharmaceutical industry
• Senior staff in healthcare authorities relevant to India

Unique Benefits When You Order This Report:

• - Original primary research and analyses. You will not find this information anywhere else
• - Full searchable report when you buy the company or corporate editions
• - Copies can be printed off for offline reading
• - Packed with charts, analysis, figures, graphs and tables

Great Potential for the Indian Pharma Sector and Market from Present Onwards, Visiongain Concludes

Currently, India' s largest selling medicines are anti-infective agents, but the fast growing areas are the lifestyle-related diseases, the foreign multinational companies will benefit from selling innovative treatments for these conditions.

With increasing prevalence of diseases of aging and lifestyle-related diseases associated with greater affluence, India' s pharmaceutical market will continue to increase steadily in sales value from 2008 onwards. Furthermore, with rapid increase in drug resistance for anti-infective agents like anti-TB, anti-malarial and other antibiotics, visiongain further emphasises that there will be a particularly strong market for most types of pharmaceutical agents - both new and established - from 2008 to 2023.

Table of Contents

1 Executive Summary: India' s Pharmaceutical Sector 2008-2023

• 1.1 Prospects for India' s Pharmaceutical Market
• 1.2 Aim, Scope and Format of the Report

2 Introduction to India' s Pharmaceutical Sector

• 2.1 Historical Developments and Prospects for India' s Pharmaceutical Sector
  • 2.1.1 India' s Early Years before 1970
  • 2.1.2 Impetus for Increased Domestic Production 1970s
  • 2.1.3 Development Phase 1980s and Growth Phase 1990s
  • 2.1.4 Indian Pharmaceutical Industry Status in 2000s
• 2.3 Foreign Policy of India Related to Pharmaceutical Sector
• 2.4 India' s GDP to Grow Significantly
• 2.5 India' s Market Abroad
• 2.6 India' s Purchasing Power Parity
• 2.7 Disease Epidemiology
  • 2.7.1 Malaria
  • 2.7.2 TB
  • 2.7.3 HIV/AIDS
  • 2.7.4 Pneumonia
  • 2.7.5 Diarrhoea
  • 2.7.6 Cancer
  • 2.7.7 Cardiovascular Diseases
  • 2.7.8 Diabetes
  • 2.7.9 Asthma and Bronchitis
  • 2.7.10 Neurological and Psychiatric Disorders and Addictions
• 2.8 Trend in Market for Individual Therapeutic Area

3 Analysis of the Indian Pharmaceutical Market

• 3.1 Pharmaceutical Market Analysis
• 3.2 Estimated Market Value for India' s OTC Market
• 3.3 Estimated Market Value for India' s Prescription Market
• 3.4 Estimated Market Volume for India' s Generic Market
• 3.5 Branded Products Will Take Significant Market Share from 2008 to 2023
• 3.6 India' s Major Selling Medicines
• 3.7 Sales Figure for Major Therapeutics Areas
• 3.8 Forecasts for Major Therapeutics Market: Anti-Infective
• 3.9 Forecasts for Major Therapeutics Market: Other Than Anti-Infective
• 3.10 Growth Rate in India' s Therapeutic Market

4 Contract Manufacturing Businesses in India

• 4.1 Forecasts for Contract Manufacturing Services
• 4.2 Contract Manufacturing in India
  • 4.2.1 Drivers for Contract Manufacturing for Outsourcing to India
• 4.3 Contract Manufacturing and Role of Indian Companies
  • 4.3.1 Outsourcing for Generics
  • 4.3.2 Sourcing Generics from Non-Competitors
  • 4.3.3 Divi' s Laboratories' Business Model
  • 4.3.4 Granules India for Production of Generic Prescription Medicines and OTCs
  • 4.3.5 Matrix Contract Manufacturer for CNS Products
  • 4.3.6 Neuland Focused on Anti-Bacterials
  • 4.3.7 Natco Chose Chronic Diseases
• 4.4 Enforcing GMP Compliance for APIs in EU
• 4.5 Growth in Biotechnology Sector of India
  • 4.5.1 Ranbaxy' s Entry Into Biotechnology

5 Contract Research Businesses in India

• 5.1 Forecasts for Contract Research
• 5.2 Focus on Innovative R&D
• 5.3 CROs to Maintain High Quality
• 5.4 Drivers and Restrains for Outsourcing Clinical Research Services from India
• 5.5 Contract Research and Companies
  • 5.5.1 R&D Investments by Foreign MNCs in India
  • 5.5.2 Vimta is an Emerging Company
  • 5.5.3 Suven is Emerging as a Contract R&D Focused
  • 5.5.4 Wellquest is a CRO Compliant with International Regulatory Norms
• 5.6 Outsourcing Clinical Data Management
  • 5.6.1 GlaxoSmithKline to Outsource Data Management
  • 5.6.2 Clininvent is a CRO with Standardised Data Management Skills
• 5.7 Emerging Outsourcing Models
• 5.8 National Drug Authority to be Formed
• 5.9 Firsthand Interview for Expert Opinion on Clinical Research 1
  • 5.9.1 Small and Medium Sized Companies Opt For CROs
  • 5.9.2 Pros and Cons of Contract Research Services from India
  • 5.9.3 India' s Own Innovative Products
  • 5.9.4 Differences between India and China for Undertaking Trials
• 5.10 Firsthand Interview for Expert Opinion on Clinical Research 2
  • 5.10.1 Asian Nations with Proven Efficacy to Undertake Clinical Trials
• 5.11 Firsthand Interview for Expert Opinion on Clinical Research 3
  • 5.11.1 Pros and Cons of Contract Research Services from India

6 India' s Pharmaceutical Company Profile and Opportunities with Them

• 6.1 Suitable Business Models for Individual Pharmaceutical Companies in India
  • 6.1.1 Merger and Acquisition (M&A) for Indian Companies
    • 6.1.1.1 Dr Reddy Acquires Betapharm
  • 6.1.2 Indian Pharmaceutical Companies Enter World Market
    • 6.1.2.1 Zyday Cadila
    • 6.1.2.2 Sun
    • 6.1.2.3 Alkem
    • 6.1.2.4 Wockhardt
    • 6.1.2.5 Lupin
    • 6.1.2.6 Ranbaxy
    • 6.1.2.7 Cipla
  • 6.1.3 Collaboration for Expansion and Improvement
  • 6.1.4 Good Manufacturing Practice (GMP) Compliance
  • 6.1.5 Foreign MNCs Maintain Significant Market Share in India
    • 6.1.5.1 GlaxoSmithKline' s Significant Market Share in India
    • 6.1.5.2 Pfizer Emerged as the Most Significant Pharmaceutical Patent Applicant in India

7 SWOT Analysis for India' s Pharmaceutical Market

• 7.1 The Existing Advantages of India' s Pharmaceutical Sector
• 7.2 Vision for India' s Pharmaceutical Sector
• 7.3 Goal of India' s Pharmaceutical Sector
• 7.4 Visiongain Suggests Following Strategies for India' s Pharmaceutical Sector
• 7.5 Drivers and Restrain for India' s Pharmaceutical Sector
• 7.6 India' s Changing Demographic Profile
  • 7.6.1 Public Healthcare System
  • 7.6.2 Private Sector Contribution to Healthcare
  • 7.6.3 Uneven Distribution of Healthcare
• 7.7 India' s Pricing Pattern for Pharmaceutical Industry
  • 7.7.1 Private Spending for Healthcare
  • 7.7.2 Wholesale Distribution and Price Regulation
• 7.8 Firsthand Interview for Expert Opinion 1
  • 7.8.1 Bureaucracy as Obstacles
  • 7.8.2 Improving Access to Rural Areas
  • 7.8.3 Therapeutic Areas to Get Increased Attention from 2008 to 2023
  • 7.8.4 Drug Resistance for Antibiotics as Unmet Needs
• 7.9 Firsthand Interview for Expert Opinion 2
  • 7.9.1 India' s Key Strength
  • 7.9.2 India' s Edge Over China In Pharmaceutical Business
  • 7.9.3 Need for Routine Inspection of Outsourcing Sites
  • 7.9.4 Need for Creation of Economic Zone for Pharmaceutical Industry
  • 7.9.5 Business Approach Needed for Rural Mass
  • 7.9.6 India as an Emerging Market
  • 7.9.7 Growth of India' s Medical Tourism
  • 7.9.8 Tropical Diseases Widespread in India
  • 7.9.9 Vertical Integration Recommended for India' s Companies
  • 7.9.10 India' s Emergence as a Major Pharmaceutical Market

8 Conclusions

• 8.1 India' s Progress in Healthcare
• 8.2 Increases in Demand for Private Healthcare
• 8.3 Increases in Patient Demand for Service Provision
• 8.4 India' s Progress in Pharmaceuticals and Outsourcing Services
• 8.5 Recommendations for India' s Pharmaceutical Sector
• 8.6 Recommendations to Foreign Pharmaceutical Companies for India' s Market

Tables

• Table 1.1 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Table 3.1 Pharmaceutical Sales ($bn) of Top 20 Nations, 2006
• Table 3.2 India' s Total Pharmaceutical Sales ($m), 2008-2014
• Table 3.3 India' s Total Pharmaceutical Sales ($m), 2015-2023
• Table 3.4 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Table 3.5 Forecasts for India' s International OTC Market ($m), 2006- 2014
• Table 3.6 Forecasts for India' s International OTC Market ($m), 2015-2023
• Table 3.7 Forecasts for India' s Domestic OTC Market,($m), 2006-2014
• Table 3.8 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
• Table 3.9 Forecasts for India' s Prescription Market ($m), 2006-2014
• Table 3.10 Forecasts for India' s Prescription Market ($m), 2015-2023
• Table 3.11 Forecasts for Cephalosporins Sales ($m), 2006-2014
• Table 3.12 Forecasts for Cephalosporins Sales( $m), 2015-2023
• Table 3.13 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006-2014
• Table 3.14 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015-2023
• Table 3.15 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
• Table 3.16 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
• Table 3.17 Forecasts for Macrolides Sales ($m), 2006-2014
• Table 3.18 Forecasts for Macrolides Sales ($m), 2015-2023
• Table 3.19 Forecasts for Anti-Malarial Sales ($m), 2006-2014
• Table 3.20 Forecasts for Anti-Malarial Sales($m), 2015-2023
• Table 3.21 Forecasts for Anti-TB Sales ($m), 2006-2014
• Table 3.22 Forecasts for Anti-TB Sales ($m), 2015 -2023
• Table 3.23 Forecasts for Anti-Diarrhoeal Sales($m), 2006-2014
• Table 3.24 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
• Table 3.25 Forecasts for Amoebicides Sales($m), 2006-2014
• Table 3.26 Forecasts for Amoebicides Sales ($m), 2015-2023
• Table 3.27 Forecasts for NSAID Sales ($m), 2006-2014
• Table 3.28 Forecasts for NSAID Sales ($m), 2015-2023
• Table 3.29 Forecasts for H2 Receptor Blockers Sales($m), 2006-2014
• Table 3.30 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
• Table 3.31 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
• Table 3.32 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
• Table 3.33 Forecasts for Anti-Tussives Sales ($m), 2006-2014
• Table 3.34 Forecasts for Anti-Tussives Sales ($m), 2015-2023
• Table 3.35 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
• Table 3.36 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
• Table 3.37 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
• Table 3.38 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
• Table 3.39 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
• Table 3.40 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
• Table 3.41 Forecasts for Expectorants Sales ($m), 2006-2014
• Table 3.42 Forecasts for Expectorants Sales ($m), 2015-2023
• Table 3.43 Forecasts for Topical Corticosteroids Sales ($m), 2006-2014
• Table 3.44 Forecasts for Topical Corticosteroids Sales ($m), 2015-2023
• Table 3.45 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
• Table 3.46 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
• Table 3.47 Forecasts for Antacid Sales ($m), 2006-2014
• Table 3.48 Forecasts for Antacid Sales ($m), 2015 -2023
• Table 3.49 Forecasts for Calcium Sales ($m), 2006-2014
• Table 3.50 Forecasts for Calcium Sales ($m), 2015 -2023
• Table 3.51 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
• Table 3.52 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
• Table 3.53 Forecasts for Anti-Histamine Sales ($m), 2006-2014
• Table 3.54 Forecasts for Anti-Histamine Sales ($m), 2015-2023
• Table 3.55 Forecasts for Anti-Depressant Sales ($m), 2006-2014
• Table 3.56 Forecasts for Anti-Depressant Sales ($m), 2015-2023
• Table 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m), 2006-2014
• Table 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m), 2015-2023
• Table 5.1 Forecasts for India' s Contract Research Revenues ($m), 2006-2014
• Table 5.2 Forecasts for India' s Contract Research Revenues( $m), 2015-2023
• Table 5.3 Dr Reddy' s Pipeline Strength
• Table 6.1 Fastest Growing Local Companies from Top 50 in India
• Table 6.2 Leading Local Companies from Top 100 in India
• Table 6.3 Leading Corporate Groups
• Table 6.4 Merger and Acquisition Activities of Indian Companies, 2007
• Table 6.5 International M&A of Indian Firms
• Table 7.1 SWOT Analysis for India' s Pharmaceutical Sector
• Table 7.2 India' s Demographic Profile, 2007

Figures

• Figure 1.1 Forecasts for India' s Pharmaceutical Industry' s Market ($m), 2008, 2013,2018 & 2023
• Figure 2.1 Developments and Prospects for India' s Pharmaceutical Sector (Past,Present & Future)
• Figure 2.2 India' s Pharmaceutical Industry Culture and Attributes Figure 3.1 Countries Ranked by Pharmaceutical Market Share, 2006
• Figure 3.2 Ratio of Domestic Pharmaceutical Market Share by Value with Export,2006
• Figure 3.3 India' s Total Pharmaceutical Sales ($m), 2006-2014
• Figure 3.4 India' s Total Pharmaceutical Sales ($m), 2015-2023
• Figure 3.5 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Figure 3.6 Forecasts for India' s International OTC Market ($m), 2006-2014
• Figure 3.7 Forecasts for India' s International OTC Market ($m), 2015-2023
• Figure 3.8 Forecasts for India' s Domestic OTC Market ($m), 2006-2014
• Figure 3.9 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
• Figure 3.10 Ratio for Domestic and International OTC Market Share ($m), India, 2006
• Figure 3.11 Forecasts for India' s Prescription Market ($m), 2006-2014
• Figure 3.12 Forecasts for India' s Prescription Market ($m), 2015-2023
• Figure 3.13 Proportion of India' s Generic Market Share by Volume in Global Market,2008
• Figure 3.14 Proportion of India' s Generic Market Share by Volume in Global Market,2023
• Figure 3.15 Ratio for Patent and Generic Market Share by Value, India, 2007
• Figure 3.16 Ratio for Patent and Generic Market Share by Value, India, 2023
• Figure 3.17 Major Anti-Infective Sales ($m), India, 2006
• Figure 3.18 Major Selling Prescription Medicines Other Than Anti-Infective ($m),India, 2006
• Figure 3.19 Major Selling OTC Medicines Other Than Anti-Infective ($m), India, 2006
• Figure 3.20 Ratio of Anti-Infective to Other Medicines in the Market, India, 2008
• Figure 3.21 Forecasts for Cephalosporins Sales ($m), 2006-2014
• Figure 3.22 Forecasts for Cephalosporins Sales ($m), 2015-2023
• Figure 3.23 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006- 2014
• Figure 3.24 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023
• Figure 3.25 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
• Figure 3.26 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
• Figure 3.27 Forecasts for Macrolides Sales ($m), 2006-2014
• Figure 3.28 Forecasts for Macrolides Sales ($m), 2015-2023
• Figure 3.29 Forecasts for Anti-Malarial Sales ($m), 2006-2014
• Figure 3.30 Forecasts for Anti-Malarial Sales ($m), 2015-2023
• Figure 3.31 Forecasts for Anti-TB Sales ($m), 2006-2014
• Figure 3.32 Forecasts for Anti-TB Sales ($m), 2015 -2023
• Figure 3.33 Forecasts for Anti-Diarrhoeal Sales ($m), 2006-2014
• Figure 3.34 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
• Figure 3.35 Forecasts for Amoebicides Sales ($m), 2006-2014
• Figure 3.36 Forecasts for Amoebicides Sales ($m), 2015-2023
• Figure 3.37 Forecasts for NSAIDs Sales ($m), 2006-2014
• Figure 3.38 Forecasts for NSAIDs Sales ($m), 2015-2023
• Figure 3.39 Forecasts for H2 Receptor Blockers Sales ($m), 2006-2014
• Figure 3.40 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
• Figure 3.41 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
• Figure 3.42 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
• Figure 3.43 Forecasts for Anti-Tussives Sales ($m), 2006-2014
• Figure 3.44 Forecasts for Anti-Tussives Sales ($m), 2015-2023
• Figure 3.45 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
• Figure 3.46 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
• Figure 3.47 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
• Figure 3.48 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
• Figure 3.49 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
• Figure 3.50 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
• Figure 3.51 Forecasts for Expectorants Sales ($m), 2006-2014
• Figure 3.52 Forecasts for Expectorants Sales ($m), 2015-2023
• Figure 3.53 Forecasts for Topical Corticosteroids Sales ($m), 2006- 2014
• Figure 3.54 Forecasts for Topical Corticosteroids Sales ($m), 2015- 2023
• Figure 3.55 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
• Figure 3.56 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
• Figure 3.57 Forecasts for Antacid Sales ($m), 2006-2014
• Figure 3.58 Forecasts for Antacid Sales ($m), 2015 -2023
• Figure 3.59 Forecasts for Calcium Sales ($m), 2006-2014
• Figure 3.60 Forecasts for Calcium Sales ($m), 2015 -2023
• Figure 3.61 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
• Figure 3.62 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
• Figure 3.63 Forecasts for Anti-Histamine Sales ($m), 2006-2014
• Figure 3.64 Forecasts for Anti-Histamine Sales ($m), 2015-2023
• Figure 3.65 Forecasts for Anti-Depressant Sales ($m), 2006-2014
• Figure 3.66 Forecasts for Anti-Depressant Sales ($m), 2015-2023
• Figure 3.67 Growth Rate According to Therapeutic Areas ($m), 2007
• Figure 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m), 2008-2014
• Figure 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m), 2015-2023
• Figure 4.3 Path Up the Value Chain for Indian Companies
• Figure 5.1 Forecasts for India' s Contract Research Revenues ($m), 2008-2014
• Figure 5.2 Forecasts for India' s Contract Research Revenues ($m), 2015-2023

Organisations Mentioned in the Report:

• Actavis
• Alkem
• Allen Spa
• Agency National for Vigilance Sanitaire (ANVISA)
• Advanced Medical Optics
• AstraZeneca
• Aurobindo
• Avecia
• Aventis
• Betapharm
• B-Tabs
• Bulk Drug Manufacturers Association
• Carbogen and Amcis
• Central Drugs Standards Control Organisation (CDSCO)
• Cipla
• Clininvent
• Dishman
• Divi' s
• Docpharma
• Dr. Reddy' s
• Elder
• Eli Lilly
• Emcure
• Ethimed
• FDA
• Geneva
• GlaxoSmithKline
• Government of India
• Granules India
• Hollister-Stier
• Indian Drug Manufacturers' Association
• IMS Health
• Ind-Swift
• Intas
• International Monetary Fund
• Johnson & Johnson
• Jubilant Organosys
• Lupin
• Macleods
• Mankind
• Matrix
• Medicamenta
• Medley
• Medicines and Healthcare products Regulatory Agency (MHRA)
• Medicines Control Council (MCC)
• Mundogen
• Mylan
• Natco
• National Institute of Pharmacy (NIP)
• Negma
• Neuland
• Nicholas Piramal
• Novartis
• Novo Nordisk
• Organisation of Pharmaceutical Producers of India (OPPI)
• Perigo
• Pfizer
• Pharmaceutical Inspection Convention (PIC)
• Pinewood
• Quintiles
• Ranbaxy
• Rexcel
• Rhodia
• Roche
• Sanmar API
• Sanofi-Aventis
• Shasun
• Solvay
• Sun
• Suven
• Taro
• Tata Consulting Services
• Terapia
• Therapeutic Goods Administration (TGA)
• Vimta
• Wellquest
• World Bank
• Wockhardt
• World Health Organisation (WHO)
• World Trade Organization (WTO)
• Zenotech
• Zuventus
• Zydus Cadila

相關商品

Visiongain發行的製藥相關市場調查報告書

抗菌藥物：全球市場展望 2012-2022

Antibacterial Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

多發性硬化症治療：全球藥劑市場 2012-2022

Multiple Sclerosis Treatment: World Drug Market 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

全球小分子癌症標靶治療市場：2011-2021

Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

價格 : US $ 2642

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!